Plasma Proteins of Hemostasis in the Hepatointestinal Form of Schistosomiasis Mansoni

Camacho-Lobato, Luciana; Borges, Durval Rosa
October 1996
Clinical & Applied Thrombosis/Hemostasis;Fall1996, Vol. 2 Issue 4, p276
Academic Journal
The hepatosplenic form of schistosomiasis mansoni is associated with impairment of blood coagulation, a result of reduced synthesis of clotting factors and inhibitors, enhanced fibrinolytic activity, or "consumption" of plasma clotting proteins. The pathogenesis of the latter mechanism has not been elucidated. Schistosoma mansoni (Sm) has a long lifespan as an intravascular fluke, probably a consequence of its ability to evade host immunologic defense mechanisms. In order to determine if the parasite is able to disturb hemostasis in vivo, we studied 21 non-alcoholics with normal body mass index, and HBsAg, anti-HBc, and anti-HCV negative adult males, who were not using drugs. Eleven had the hepatointestinal form of the disease, with viable Sm ova in stools, and 10 were healthy volunteers (control group). Blood specimens were drawn by a two-syringe technique for both the performance of liver tests and determination of hemostasis proteins (prothrombin, antithrombin III, protein C, protein S, high-molecular-weight kininogen, and plasminogen). The latter proteins were assayed immunologically in plasma using specific antibodies. Statistical analysis of the results failed to demonstrate any significant difference between the two groups. We may therefore conclude that there is no derangement of hepatic protein synthesis in the mild form of the disease and that Sm probably escapes host defense mechanisms in vivo, and does not contribute to the consumption coagulopathy described in the hepatosplenic form of the disease.


Related Articles

  • Crystal structure of the factor XI zymogen reveals a pathway for transactivation. Papagrigoriou, Evangelos; McEwan, Paul A; Walsh, Peter N; Emsley, Jonas // Nature Structural & Molecular Biology;Jun2006, Vol. 13 Issue 6, p557 

    Factor XI (FXI), a coagulation protein essential to normal hemostasis, circulates as a disulfide-linked dimer. Here we report the full-length FXI zymogen crystal structure, revealing that the protease and four apple domains assemble into a unique 'cup and saucer' architecture. The structure...

  • THE EFFECT OF COLLOIDAL SILICA ON BLOOD COAGULATION. Margolis, J. // Australian Journal of Experimental Biology & Medical Science;Jun1961, Vol. 39 Issue 3, p249 

    Focuses on the effect of colloidal silica on blood coagulation. Adsorption and partial denaturation of a specific plasma protein, the Hageman factor; Dependence of the activity of the silica on the particle diameter.

  • Blood coagulation and fibrinolysis after long-duration treadmill exercise controlled by individual anaerobic threshold. Hilberg, Thomas; Gläser, Doreen; Reckhart, Carsten; Prasa, Dagmar; Stürzebecher, Jörg; Gabriel, Holger H. W. // European Journal of Applied Physiology;Nov2003, Vol. 90 Issue 5/6, p639 

    For rehabilitation training it is recommended that the intensity of exercise should be clearly below the individual anaerobic threshold (IAT). We investigated blood coagulation, particularly endogenous thrombin potential (ETP) and fibrinolysis following a standardized treadmill (TR) ergometer...

  • How to Interpret and Pursue an Abnormal Prothrombin Time, Activated Partial Thromboplastin Time, and Bleeding Time in Adults. Kamal, Arif H.; Tefferi, Ayalew; Pruthi, Rajiv K. // Mayo Clinic Proceedings;Jul2007, Vol. 82 Issue 7, p864 

    The prothrombin time (PT) and activated partiai thrombopiastin time (APTT) are among the most commonly ordered coagulation tests. in 2005, more than 140,000 PT and more than 95,000 APTT tests were performed at Mayo Clinic. The most common indications for ordering these tests include...

  • factor V. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p295 

    An encyclopedia entry for "factor V" is presented. It refers to one of the blood proteins that maintains the balance between the blood clotting after an injury. It was known that about 5 percent of the population have an inherited mutation in the gene controlling factor V production and are at...

  • KaraciÄŸer hastalıklarında pıhtılaÅŸma-tromboz mekanizmasına neler oluyor? Tiraje Celkan, Tülin // Turkish Pediatrics Archive / Turk Pediatri Arsivi;Jun2013, Vol. 48 Issue 2, p94 

    Children with liver disease present complex and varied acquired coagulation abnormalities. Liver is the place where clotting factors are produced as well as inhibitors of coagulation and fibrinolytic system components. Although 75-85% of patients with liver disease show abnormal laboratory...

  • Change in Blood Coagulation Parameters After Total Body Irradiation. Cengiz, Mustafa; Göker, Hakan; Yazici, Gözde; Zorlu, Faruk; Büyükasik, Yahya; Kirazli, Serafettin; Akman, Ümit; Yildiz, Ferah; Dogan, Ali; Haznedaroglu, Ibrahim C. // International Journal of Hematology & Oncology / UHOD: Uluslarar;Sep2008, Vol. 18 Issue 3, p135 

    We aim to test the changes of coagulation parameters after the TBI by thromboelastography. Eleven patients who underwent TBI between march 2005 and march 2006 in our department were included in this study. Blood samples were taken from all patients immediately before the delivery of TBI and 12...

  • Relevance of clotting tests in liver disease. Thachil, J. // Postgraduate Medical Journal;Apr2008, Vol. 84 Issue 990, p177 

    Liver disease is associated with impairment of the haemostatic function due to the abnormal and decreased synthesis of the clotting factors. It is thus only logical to have considered assessment of the clotting profile (to include prothrombin time (PT) and activated partial thromboplastin time...

  • Research brief: Fishy future for haemophilia.  // GP: General Practitioner;9/20/2004, p10 

    The article presents information about a study conducted by researchers from Great Briatin. The researchers have extracted human coagulation factor VII from fish that have been genetically modified to include a human gene that causes their livers to produce the clotting factor.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics